Evolution of lymphocytes and NK cell-surface markers and function during the course of the treatment. (A) Evolution of total lymphocytes, B cells, T cells, and NK cells during 20 weeks of follow-up. Total lymphocytes, CD19⁺ B cells, CD3⁺ T cells, CD3⁺CD4⁺ cells, CD3⁺CD8⁺ cells, and CD3⁻CD56⁺ NK cells were quantified by flow cytometry at different time points after initiation of the treatment up to week 20 in patients treated at dose 3 mg/kg (n = 3). (B) Expression of NK receptors during the 10-week course. The figure corresponds to the mean of the density levels evaluated by flow cytometry obtained from the patients enrolled in the 0.3, 1, and 3 mg/kg dose groups. (C) Anti-KIR treatment does not impair NK function. NK function was followed for 10 weeks during the course of the treatment. Cytotoxicity was measured using ⁵¹Cr-labeled cells and degranulation using the CD107 assay.